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Mutation and translocation of fibroblast growth factor receptorsoften lead to aberrant signaling and cancer. This work focuses onthe t(8;22)(p11;q11) chromosomal translocation which creates the
breakpoint cluster region (BCR) fibroblast growth factor receptor1 (FGFR1)
(BCR-FGFR1) fusion protein. This fusion occurs in stem cell leukemia/lym-
phoma, which can progress to atypical chronic myeloid leukemia, acute
myeloid leukemia, or B-cell lymphoma. This work focuses on the biochem-
ical characterization of BCR-FGFR1 and identification of novel therapeutic
targets. The tyrosine kinase activity of FGFR1 is required for biological activ-
ity as shown using transformation assays, interleukin-3 independent cell
proliferation, and liquid chromatography/mass spectroscopy analyses.
Furthermore, BCR contributes a coiled-coil oligomerization domain, also
essential for oncogenic transformation by BCR-FGFR1. The importance of
salt bridge formation within the coiled-coil domain is demonstrated, as dis-
ruption of three salt bridges abrogates cellular transforming ability. Lastly,
BCR-FGFR1 acts as a client of the chaperonin heat shock protein 90 (Hsp90),
suggesting that BCR-FGFR1 relies on Hsp90 complex to evade proteasomal
degradation. Transformed cells expressing BCR-FGFR1 are sensitive to the
Hsp90 inhibitor Ganetespib, and also respond to combined treatment with
Ganetespib plus the FGFR inhibitor BGJ398. Collectively, these data suggest
novel therapeutic approaches for future stem cell leukemia/lymphoma treat-
ment: inhibition of BCR oligomerization by disruption of required salt
bridges; and inhibition of the chaperonin Hsp90 complex.
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ABSTRACT
Introduction
Fibroblast growth factor receptors (FGFR) are part of the receptor tyrosine kinase
(RTK) family and are responsible for cell growth and proliferation. The FGFR fam-
ily is composed of four homologous receptors; all contain three extracellular
immunoglobulin-like domains, a transmembrane domain, and a split kinase
domain. When these receptors are bound to fibroblast growth factor (FGF) and
heparin sulfate proteoglycans, they are able to dimerize, which leads to auto-phos-
phorylation of the kinase domain and activation of downstream cell signaling path-
ways including signal transducer and activator of transcription (STAT), mitogen
activated protein kinase (MAPK), protein kinase B (AKT), and phospholipase C
gamma (PLCγ). FGFR signaling results in cellular migration, cell proliferation, angio-
genesis, and wound healing.1
FGFRs are often aberrantly activated in cancer by overexpression, mutation, or
translocation. Specifically, FGFR1 is involved in stem cell leukemia/lymphoma
(SCLL), also known as 8p11 myeloproliferative syndrome (EMS).2 SCLL is charac-
terized by a chromosomal translocation that produces a dimerizing protein partner
fused to the kinase domain of FGFR1.3 Although SCLL is rare, it can aggressively
progress to atypical chronic myeloid leukemia (CML), acute myeloid leukemia
(AML), or B-cell lymphoma. Despite extensive chemotherapy, the only known cur-
ative option for SCLL patients is hematopoietic stem cell
transplantation. Although both Ponatinib and Pemigatinib
(INCB054828) have been used to treat patients with
mixed results, few other alternative treatment plans exist
for patients who are either awaiting or are unable to
receive transplantation.4,5 This work focuses on the
t(8;22)(p11;q11) chromosomal translocation resulting in
the BCR-FGFR1 fusion protein with exon 4 of the break-
point cluster region (BCR) fused to exon 9 of FGFR1.
Although BCR was first identified fused to Abelson
murine leukemia viral oncogene homolog-1 (ABL), also
known as the Philadelphia chromosome, BCR has since
then been identified fused to ret proto-oncognene (RET),
Janus kinase 2 (JAK2), and platelet derived growth factor
receptor alpha (PDGFRA).6-9 Although a common fusion
partner, the endogenous function of the BCR gene remains
obscure. The fusion protein BCR-FGFR1 retains the
coiled-coil dimerization/oligomerization domain, putative
serine/threonine kinase domain, and partial RhoGEF
domain from BCR.10
The BCR-FGFR1 fusion is not well characterized, and
this work seeks to elucidate the underlying mechanisms
behind BCR-FGFR1 mediated SCLL. Although tyrosine
kinase inhibitor therapies (TKI) are traditionally used to
treat certain hematological cancers, the use of TKI often
results in drug resistance in patients. Thus, it is crucial to
determine additional therapeutic strategies in treating
hematopoietic cancers. Here we suggest disruption of the
BCR coiled-coil dimerization domain and Hsp90 inhibi-
tion as novel therapeutic targets for BCR-FGFR1 driven
SCLL. Data presented here may also allow for additional
approaches in treating BCR-ABL mediated CML, due to
the similarity between BCR-ABL and BCR-FGFR1 fusion
proteins. 
Methods
DNA Constructs
The BCR gene (pSG65-Bcr) was purchased from Addgene
(Watertown, MA, USA) and was subcloned into pcDNA3. FGFR1
and FGFR1-K656Ewere previously described.11 To construct BCR-
FGFR1, a BamHI site was introduced by PCR-based site-directed
mutagenesis after amino acid L584 in BCR and before amino acid
V429 in FGFR1. This unique internal BamHI site was used togeth-
er with an upstream site of EcoRI to subclone the 5’ region of BCR
into the FGFR1 pCDNA3 plasmid, creating a fusion breakpoint of
BCR exon 4 fused to FGFR1 exon 9. The BamHI site adds 6 bases
which code for a GS linker between the 5’ BCR and the 3’ FGFR1.
FGFR1-K514A12 and all other mutations described were intro-
duced by PCR-based site-directed mutagenesis. FGFR1 or BCR-
FGFR1 clones were subcloned into the pLXSN expression plasmid
for use in NIH3T3 or 32D cells. Details of plasmid DNA used are
in the Online Supplementary Material and Methods.
Cell transfection, immunoprecipitation, immunoblot
analysis
HEK293T cells were transfected with 3 mg of the pcDNA3 plas-
mid constructs using calcium phosphate transfection as
described.13 Immunoblotting was performed as described.14
NIH3T3 focus assays were performed as described.15 Number of
foci were, normalized by transfection efficiency, and quantitated
relative to a positive control +/-standard error of the mean (SEM). 
The Hsp90 inhibitor, Ganetespib was added to HEK293T trans-
fected cells at a concentration of 200 nM for 4 hours (h) during cell
starvation at 10% CO2, 37°C. Transfected NIH3T3 cells were
maintained with 0, 10, 20, 23, 25, or 30 nM Ganetespib for 14
days, and fixed and scored as described. For combination drug
treatment, 15 nM Ganetespib was used with the FGFR inhibitor
BGJ398 at 0, 2.5, or 10 nM. All cell assays were performed a min-
imum of three times. More detailed information is provided in the
Online Supplementary Materials and Methods.
Interleukin-3 (IL-3) independent growth in 32D cells 
A total of 1x106 32D cells were electroporated (1,500V, 10 ms, 3
pulses) by Neon Transfection system using 30 mg of FGFR1 or
BCR-FGFR1 derivatives in pLXSN in triplicate. 48 h after transfec-
tion, cells were selected with 1.5 mg/mL Geneticin (G418) for 10
days to generate stable cell lines before starting IL-3 independent
growth assays. Triplicate flasks were seeded with the cell lines at
4x104 cell/mL in the presence or absence of mouse IL-3. In addi-
tion, 1 nmol/L of FGF and 30 ug/mL of heparin was added to a set
of flasks in the absence of IL-3. On days 1, 3, 5, 7, and 9 samples
were counted and measured for MTT metabolic activity as
described.16 For Ganetespib treatment, cells were seeded with 0,
2.5, or 5.0 nM Ganetespib –/+ IL-3. MTT metabolic activity was
measured on days 3, 5, and 7. A concentration of 10 nM or higher
of Ganetespib was found to be toxic to 32D cells in the presence
of IL-3.
Mass spectrometry sample preparation
Liquid chromatography/mass spectroscopy (LC-MS/MS) for
phosphopeptide analysis was as described previously.16 Complete
information is available in the Online Supplementary Material and
Methods.  
Results 
Signaling cascade activation by BCR-FGFR1
The role of BCR in this fusion protein has remained
unclear, as BCR-FGFR1 retains the coiled-coil oligomeriza-
tion domain, putative serine/threonine kinase domain,
and partial RhoGEF domain from BCR. In order to eluci-
date if BCR-FGFR1 relies on the tyrosine kinase activity of
FGFR1, a K514A kinase dead mutation,12 or a K656E
kinase activating mutation,11,15 were introduced in the
FGFR1 tyrosine kinase domain in both FGFR1 and BCR-
FGFR1 backgrounds (Figure 1A). These studies were per-
formed in HEK293T cells, as they have previously been
used in FGFR signal transduction and protein phosphory-
lation studies.16 HEK293T cells expressing either full-
length FGFR1 or BCR-FGFR1 variants were analyzed for
MAPK, STAT3 and STAT5 activation, and FGFR1 receptor
phosphorylation. Expression of FGFR1 shows slight acti-
vation of the MAPK pathway, while expression of the
activated FGFR1-K656E shows elevated phosphorylation
levels of MAPK (Figure 1B, panel 7). Expression of BCR-
FGFR1 or BCR-FGFR1-K656E also resulted in MAPK phos-
phorylation. Additionally, STAT3 and STAT5 phosphory-
lation were strongly elevated by BCR-FGFR1 and BCR-
FGFR1-K656E, in comparison to FGFR1 or FGFR1-K656E,
indicating that BCR-FGFR1 induces both MAPK and STAT
pathway activation (Figure 1B, panel 3 and 5). 
To examine the phosphorylation of each fusion con-
struct compared with FGFR1, FGFR1-K656E and FGFR1-
K514A were expressed in HEK293T cells, collected and
immunoprecipitated with a C-terminal FGFR1 antibody,
and probed for tyrosine phosphorylation. An increase in
tyrosine phosphorylation was observed in both BCR-
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FGFR1, and BCR-FGFR1-K656E expressing cells, when
compared to FGFR1, indicating that the contribution of
BCR as a partner gene to this fusion increases the consti-
tutive phosphorylation of FGFR1 (Figure 1B, top panel).
Interestingly, although the putative serine/threonine
kinase domain in BCR is present in the BCR-FGFR1 fusion
protein, HEK293T cells expressing BCR-FGFR1-K514A,
which contains BCR fused to a kinase-dead FGFR1, does
not activate MAPK or STAT pathways (Figure 1B). In addi-
tion, no tyrosine phosphorylation of FGFR1 was detected
for cells expressing BCR-FGFR1-K514A, suggesting that
BCR-FGFR1 relies on the constitutive kinase activity of
FGFR1 for activation of downstream cell signaling. 
Cell transforming ability of BCR-FGFR1 by focus assay
In order to investigate the transforming ability of BCR-
FGFR1 and subsequent mutants, these constructs were
assayed in a NIH3T3 cell transforming assay. NIH3T3 cell
transformation assays were one of the original assays used
to discover and characterize novel oncogenes such as acti-
vated RAS, MUC4, AKT and various other oncogenes.16,17
NIH3T3 cells expressing BCR-FGFR1, BCR-FGFR1-K656E,
and FGFR1-K656E exhibited high levels of focus forma-
tion (Figure 2B, D and G). FGFR3-TACC3, a known fusion
oncogene,15,16 was used as a positive control. Interestingly,
BCR-FGFR1 and BCR-FGFR1-K656E exhibited nearly
three-fold higher focus formation in comparison to
FGFR3-TACC3. NIH3T3 cells expressing either FGFR1,
FGFR1-K514A, or BCR-FGFR1-K514A did not form any
visible foci (Figure 2C, E-F), indicating that the kinase
activity of FGFR1 is critical to the transforming ability of
this fusion. 
BCR-FGFR1 promotes IL-3 independent cell growth  
The BCR-FGFR1 fusion protein has been solely discov-
ered in hematopoietic cancers to date. Previous studies
have utilized either Ba/F3 or 32D hematopoietic cell lines
to demonstrate oncogenic and proliferative potential in
these IL-3 dependent cell lines.16,18 32D cells were used to
investigate the proliferative potential of cells expressing
FGFR and BCR-FGFR1 derivatives in the presence and
absence of IL-3, and in the absence or presence of aFGF
(Figure 3).
FGFR1, FGFR1-K656E, BCR-FGFR1, and BCR-FGFR1-
K656E were electroporated into 32D cells. Only 32D cells
which expressed either BCR-FGFR1 or BCR-FGFR1-
K656E were able to proliferate in the absence of IL-3, as
seen through MTT metabolic assays and cell counts
(Figure 3A and D). The addition of aFGF in the absence of
IL-3 resulted in a slight increase in cell growth for FGFR1
and FGFR1-K656E, but no change for BCR-FGFR or BCR-
FGFR1-K656E (Figure 3B and E), as expected since the
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Figure 1. Cell signaling activated by BCR-FGFR1. (A) Schematic of FGFR1 and BCR-FGFR1 with K514A kinase dead, and K656E kinase activating mutations shown.
FGFR1 contains an extracellular ligand binding domain with immunoglobulin-like domains (Ig), a transmembrane domain (TM), a split tyrosine kinase domain, and
kinase insert domain (KI). BCR-FGFR1 contains breakpoint cluster region (BCR) exon 4 at the N-terminus fused to the kinase domain of fibroblast growth factor recep-
tor 1 (FGFR1) at exon 9. BCR contributes a coiled-coil (CC) and a putative serine/threonine (S/T) kinase domain to the BCR-FGFR1 fusion. (B) Lysates of HEK293T
cells expressing either FGFR1 or BCR-FGFR1 derivatives were immunoprecipitated with anti-FGFR1 antibody and immunobotted with phosphotyrosine antibody
(panel 1). These lysates were immunoblotted with anti-FGFR1 antibody to detect expression of transfected clones (panel 2). Lysates were examined for activation of
the STAT3, STAT5 and MAPK pathways using phospho-specific antibodies; phospho-STAT3 (Y705) (panel 3), phospho-STAT5 (Y694) (panel 5) and phospho-MAPK
(T202/Y204) (panel 7). Membranes were stripped and reprobed for total STAT3, STAT5 and MAPK shown in panels 4, 6 and 8, respectively.
A B
extracellular ligand binding domain of FGFR1 is removed
in the fusion proteins. All transfected constructs displayed
cell viability in the presence of IL-3 (Figure 3C and F).
Thus, these data demonstrate that the BCR-FGFR1 fusion
protein requires the N-terminal contribution of BCR for
IL-3-independent proliferation as assayed in 32D cells. 
LC-MS/MS analysis identifies novel phosphorylation
sites
The strong tyrosine phosphorylation signal seen in
BCR-FGFR1 and BCR-FGFR1-K656E lysates though
immunoblotting (Figure 1) led to the inquiry of whether
there were any novel phosphorylation sites within these
fusion proteins. To investigate this question, HEK293T
cell lysate expressing either FGFR1 or BCR-FGFR1 deriva-
tives were immunoprecipitated and analyzed by LC-
MS/MS as described.16
Both BCR-FGFR1 and BCR-FGFR1-K656E exhibit high
phosphorylation levels on key tyrosine residues in the
FGFR1 kinase domain, whereas BCR-FGFR1-K514A
exhibited only slight phosphorylation (Figure 4). The lack
of phosphorylation on the activation loop tyrosine
residues in BCR-FGFR1-K514A indicates that FGFR1
kinase activity is critical for activation of the BCR-FGFR1
fusion.
Additional serine, threonine, and tyrosine phosphoryla-
tion sites were also detected in BCR-FGFR1 or BCR-
FGFR1-K656E (Figure 4B-C) which have not been previ-
ously reported. To determine the role of these novel phos-
phoacceptor sites within the BCR domain of BCR-FGFR1
fusion proteins, phosphorylated serine or threonine
residues were mutated to alanine, and phosphorylated
tyrosine residues in BCR were mutated to phenylalanine.
Each construct was assayed for focus formation. In addi-
tion to these mutations, a BCR(Y177F)-FGFR1 mutant was
also assayed as it mutates the Grb2 binding site, previous-
ly shown to reduce activation of the BCR-FGFR1 fusion
protein.19,20
The Y177F Grb2 mutation in BCR-FGFR1 shows a 50%
decrease in transforming ability when compared to
NIH3T3 cells expressing BCR-FGFR1. However, all addi-
tional mutations in BCR phosphoacceptor sites displayed
little to no difference in transforming ability (Table 1). The
mutant BCR(T359A/S367A/S369A/S377A)-FGFR1, which
mutates phosphorylated residues within the ABL SH2
binding domain present in BCR, was also transforming.
Taken together, LC-MS/MS data and cell transformation
assays suggest that tyrosine phosphorylation on activation
loop residues within the FGFR1 kinase domain is critical
for BCR-FGFR1 activation. BCR-FGFR1 relies on an active
BCR-FGFR1 regulated by dimerization and chaperonin Hsp90 
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Figure 2. Cell transformation of NIH3T3 cells by
BCR-FGFR1. Representative plates from a focus
assay are shown, with transfected constructs
indicated. The graph shows the number of foci
scored, normalized for transfection efficiency
and calculated as a percentage of transforma-
tion relative to FGFR3-TACC3 –/+ standard error
of the mean (SEM). Assays were performed a
minimum of three times per each DNA con-
struct. 
FGFR1 kinase domain for transformation, while phospho-
rylation on residues within the BCR domain does not
appear to be critical.
Salt bridge disruption in BCR dimerization domain
abrogates cell transforming ability
The coiled-coil oligomerization domain of BCR is an
attractive therapeutic target, as it is essential for cell trans-
formation as demonstrated with assays done in BCR-
ABL.21 Previous work has shown the necessity of salt
bridge formation for the activation of oncogenic fusion
protein ETV6-NTRK3, which is found in AML.22 Here we
investigated the importance of salt bridge formation in the
BCR coiled-coil domain as a potential requirement for the
oligomerization and oncogenic activation of BCR-FGFR1.
The coiled-coil oligomerization region of BCR spans
amino acid residues 3-75 and has been proposed to con-
tain two interhelical salt bridges stabilizing the two coils
in an antiparallel coiled-coil23 (Figure 5). The first salt
bridge (Salt Bridge #1) was proposed to form between
residues Glu34 and Arg55, whereas the second salt bridge
(Salt Bridge #2), between Glu46 and Arg53 is visible in the
crystal structure of the BCR oligomerization domain
(Figure 5B).23-25 Each salt bridge residue was individually
mutated to a residue of the opposite charge to abolish the
electrostatic interaction. When residues Glu34 or Arg55 in
BCR Salt Bridge #1 were mutated to the opposing charge,
E34R or R55E respectively, little to no effect was observed
in cell transformation (Figure 5C, mutants 2 and 8).
Likewise, when residues Glu46 or Arg53 in BCR Salt
Bridge #2 were mutated to the opposing charge, E46R or
R53E respectively, no effect in cell transformation was
observed (Figure 5C, mutants 3-4).
We also became aware of the possible importance of a
putative intrahelical salt bridge (Salt Bridge #3) involving
E52 and R5523 (Figure 5A-B). Since R55 is also involved in
Salt Bridge #1, this means that mutation of R55E to probe
the importance of Salt Bridge #1 inadvertently disrupts the
intrahelical Salt Bridge #3. This extra layer of complexity
was analyzed as shown in Table 2. The upper portion of
M.N. Peiris et al.
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Figure 3. BCR-FGFR1 supports interleukin-3-independent proliferation. 32D control cells and cell lines selectively expressing FGFR1, FGFR1-K656E (FGFR1*), BCR-
FGFR1 and BCR-FGFR1-K656E (BCR-FGFR1*) were cultured in the absence of interleukin-3 (IL-3) (A and D), in the presence of aFGF/Heparin (B and E) and in the
presence of IL-3 (C and F). Total number of cells were counted on days 1, 3, 5, 7 and 9 to examine IL-3 independent growth (A, B, and C). Cell viability was determined
by MTT metabolic assay (D, E, and F). All control cells and cell lines were assayed in triplicate. Standard deviation is shown.
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the table lists all possible mutations in Salt Bridges #1 and
#2 (mutants 2-5) which do not disrupt Salt Bridge #3. The
lower portion of the table lists all possible mutations in
Salt Bridges #1 and #2 which also perturb Salt Bridge #3
(mutants 7-12).
When only Salt Bridge #3 was disrupted in the E52R
mutation (Figure 5C, mutant 6), little effect was observed.
When various combinations of mutations were examined,
affecting Salt Bridge #3 together with either Salt Bridge #1
or Salt Bridge #2, the effects on biological activity were
variable (Figure 5C, mutants 7-10). However, cell-trans-
forming ability by BCR-FGFR1 was significantly reduced
or completely abrogated when all three salt bridges were
disrupted simultaneously: the mutant E34R/E46R/E52R
exhibited <1% transformation activity, and the mutant
R53E/R55E exhibited only 14% (Figure 5C, mutants 
11-12). These data suggest that these three salt bridges in
the BCR coiled-coil domain together provide a critical and
partially redundant role in the oligomerization and activa-
tion of BCR-FGFR1. Figure 5D presents focus assay plates
for BCR-FGFR1 (Figure 5D, mutant 1), and for selected
mutants that disrupt either 2 or 3 salt bridge simultaneous-
ly (Figure 5D, mutants 5, 7, 9-12).
BCR-FGFR1 is an HSP90 addicted oncoprotein
Hsp90 is a highly conserved, ubiquitously expressed
molecular chaperone that controls the stability of certain
proteins.26 Prior work has shown that Hsp90 is overex-
pressed in certain cancers, and the Hsp90 complex pro-
vides stability for various oncogenic proteins, which are
necessary for cancer cell survival.27 Many of these onco-
genes, such as mutated P53 or BCR-ABL take advantage of
BCR-FGFR1 regulated by dimerization and chaperonin Hsp90 
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Figure 4. Phosphorylated residues
in BCR-FGFR1 derivatives identi-
fied by mass spectrometry analy-
sis. FGFR1 and BCR-FGFR1 deriva-
tives were transfected into
HEK293T cells and examined for
phosphorylation by mass spec-
trometry as described in the
Methods. The phosphorylation
sites are indicated that were
greater than 1% of the total phos-
phorylation detected in the sam-
ple. P-Tyr is shown in red; P-Thr is
shown in green; P-Ser is shown in
blue. Duplicate, independent sam-
ples were averaged; (A) BCR-
FGFR1-K514A, (B) BCR-FGFR1, (C)
BCR-FGFR1-K656E. There was no
significant difference in the phos-
phorylation sites detected in the
FGFR1 kinase domains in BCR-
FGFR1 fusions compared to the
FGFR1 derivatives (data not
shown). (D) A schematic presenta-
tion of the BCR-FGFR1 fusion pro-
tein with key amino acid positions
and domains labeled. The
oligomerization domain (OLIGO),
the Grb2 and the Abl SH2 binding
domains are shown. Also shown is
the partial DBL-homologous (DBL)
domain, which is a structural
RhoGEF domain of guanine
nucleotide exchange factors for
Rho/Rac/Cdc42-like GTPases. 
A
B
C
the Hsp90 chaperone system to avoid ubiquitination and
proteasomal degradation.28 Here, we aim to uncover if
BCR-FGFR1 is a client of Hsp90 and possibly relies on the
Hsp90 complex for stability and cellular survival.
HEK293T cell lysate expressing either FGFR1 or BCR-
FGFR1 derivatives were immunoprecipitated with FGFR1
antisera and immunoblotted for Hsp90. An interaction
was observed between Hsp90 and BCR-FGFR1 deriva-
tives (Figure 6A). To further analyze if BCR-FGFR1 is
dependent on Hsp90 for cellular stability and activity,
assays with potent Hsp90 inhibitor, Ganetespib, were
performed. HEK293T cells expressing either FGFR1 or
BCR-FGFR1 derivatives were treated with 200 nM
Ganetespib for 4 h, then analyzed for overall FGFR1
expression and activation of downstream cell signaling
pathways (Figure 6B). A significant reduction in BCR-
FGFR1 expression is observed following Ganetespib
M.N. Peiris et al.
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Table 1. Biological activity of mutations in phosphoacceptor sites.
Construct                                             Foci relative to             SEM (%)
                                                            BCR-FGFR1 (%)
Mock                                                                             0                                    0
BCR-FGFR1                                                               100                                 11
BCR(Y177F)-FGFR1                                                 55                                  16
BCR(Y436F)-FGFR1                                                120                                  2
BCR(Y455F)-FGFR1                                                108                                  9
BCR(S122A)-FGFR1                                                 97                                   1
BCR(Y246F)-FGFR1                                                105                                  7
BCR(S459A)-FGFR1                                                129                                  1
BCR(Y554F)-FGFR1                                                126                                 11
BCR(T359A/S367A/S369A/S377A)-FGFR1            129                                  3
BCR: breakpoint cluster region; FGFR1: fibroblast growth factor receptor 1; SEM: stan-
dard error of the mean.
Figure 5. Three salt bridges are required for BCR-
FGFR1 activity. Focus assay results with salt
bridge mutations made in BCR coiled-coil domain.
(A) The anti-parallel heptad repeats of the coiled-
coil domain of BCR showing the residues in the
“e” and “g” positions.23 The two interhelical salt
bridges are indicated between residues E34 and
R55 (#1) in the “g” positions, and between E46
and R53 (#2) in the “e” positions. Below, residues
30 through 65 of the anti-parallel region are
shown with the salt bridges indicated. Also shown
in the linear sequence is the location of the 
intrahelical salt bridge involving E52-R55 in the
“d” and “g” positions. (B) The crystal structure of
the breakpoint cluster region (BCR) coiled-coil
oligomerization domain is shown (PDB code
1K1F), as viewed using Chimera software.24,25
Positive residues R53 and R55 are in blue while
negative residues E34, E46, and E52 are in red.
(C) Results from NIH3T3 transformation assay
expressing BCR-FGFR1 fusions with salt bridge
mutations. Foci were scored, normalized for trans-
fection efficiency and quantitated relative to BCR-
FGFR1 –/+ standard error of the mean (SEM).
Each DNA construct was assayed at least three
times. (D) Representative plates from a focus
assay are shown. In the interest of space, plates
are shown only for selected mutants that disrupt
either two or three salt bridges simultaneously, as
indicated.
A B
C
D
treatment (Figure 6B, top panel). Furthermore, treatment
with this Hsp90 inhibitor shows a decrease in phospho-
rylated STAT3, and complete ablation of phosphorylated
Tyr on BCR-FGFR1, when compared to control cells
treated (Figure 6B, panel 4 and 6). Interestingly, MAPK
retains phosphorylation, despite the loss of phosphorylat-
ed BCR-FGFR1 (Figure 6B, panel 2). Although unexpect-
ed, this result could be due to the Grb2 binding site pres-
ent in BCR, which activates downstream Ras and MAPK
pathways independently of FGFR1 activation.19 The dra-
BCR-FGFR1 regulated by dimerization and chaperonin Hsp90 
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Table 2. Mutations affecting interhelical Salt Bridges #1 and/or #2, and intrahelical Salt Bridge #3. Mutated residues shown in bold font; missing
salt bridge indicated by ⨂ . Wt: wild-type.
Mutant Name                         Mutated Salt                     Salt Bridge #1               Salt Bridge #2                        Salt Bridge #3                  Activity
                                                    Bridges                              Residues                        Residues                                 Residues                             
(1) BCR-FGFR1 WT                            None                                      E34 • R55                            E46 • R53                                       E52 • R55                             Active
(2) E34R                                                   #1                                      E34R⨂ R55                        E46 • R53                                       E52 • R55                             Active
(3) E46R                                                   #2                                         E34 • R55                        E46R ⨂ R53                                   E52 • R55                             Active
(4) R53E                                                   #2                                         E34 • R55                        E46 ⨂ R53E                                    E52 • R55                             Active
(5) E34R/E46R                                     #1 + 2                                  E34R⨂ R55                     E46R ⨂ R53                                   E52 • R55                             Active
(6) E52R                                                   #3                                         E34 • R55                            E46 • R53                                   E52R ⨂ R55                          Active
(7) E34R/E52R                                     #3 + 1                                  E34R ⨂ R55                        E46 • R53                                   E52R ⨂ R55                       Reduced
(8) R55E                                               #3 + 1                                   E34 ⨂ R55E                         E46 • R53                                   E52 ⨂ R55E                          Active
(9) E46R/E52R                                     #3 + 2                                     E34 • R55                        E46R ⨂ R53                                E52R ⨂ R55                          Active
(10) R53E/E52R                                   #3 + 2                                     E34 • R55                        E46 ⨂ R53E                                E52R ⨂ R55                          Active
(11) E34R/E46R/E52R                     #3 + 1 +2                               E34R ⨂ R55                      E46 ⨂ R53                                 E52R ⨂ R55                        Inactive
(12) R55E/R53E                               #3 + 1 +2                               E34 ⨂ R55E                     E46 ⨂ R53E                                E52 ⨂ R55E                       Reduced
Figure 6. BCR-FGFR1 activity relies upon Hsp90. (A) Lysates from HEK293T cells expressing FGFR1 and BCR-FGFR1 derivatives were immunoprecipitated with
FGFR1 and immunoblotted with anti-Hsp90 antibody (top panel). The membrane was reprobed for total FGFR1 (panel 2). The bottom panel shows the Hsp90 expres-
sion in lysate samples. (B) HEK293T cells expressing FGFR1 and BCR-FGFR1 derivatives were treated with –/+ 200 nM Ganetespib for 4 hours (h) prior to lysing.
Lysates were examined for expression of the clones with anti-FGFR1 (panel 1), examined for activation of MAPK and STAT3 pathways using phospho-specific antibod-
ies; phospho-MAPK (T202/Y204) (panel 2) and phospho-STAT3 (Y705) (panel 4). Membranes were stripped and reprobed for total MAPK and STAT3 shown in panel
3 and 5, respectively. Tyrosine phosphorylation of FGFR1 and BCR-FGFR1 derivatives was examined by immunoprecipitating FGFR1 followed by immunoblotting with
anti-phosphotyrosine antibody (panel 6). The Hsp90 interaction was examined by immunoblotting with anti-Hsp90 antibody on FGFR1 immunoprecipitations (panel
7). The bottom control panel shows expression of GAPDH.
A B
matic decrease in BCR-FGFR1 expression with the addi-
tion of Ganetespib suggests that BCR-FGFR1 may be a
client protein of Hsp90 and potentially uses the Hsp90
complex for protein stability within the cell. 
To investigate if BCR-FGFR1 relies on Hsp90 for cell
transformation, NIH3T3 cells expressing FGFR1 or BCR-
FGFR1 derivatives were treated with increasing concentra-
tions of Ganetespib. Ganetespib concentrations were
titrated to allow for a dose that effectively treated BCR-
FGFR1 expressing cells without harming non-expressing
NIH3T3 cells. A reduction of cell transformation and focus
formation is observed with increasing concentrations of
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Figure 7. Effects of Ganetespib on BCR-FGFR1 activity
in cellular assays. (A) NIH3T3 transformation assay.
Cells expressing FGFR1-K656E, BCR-FGFR1 and BCR-
FGFR1-K656E were treated with increasing concentra-
tions of the Hsp90 inhibitor, Ganetespib (10, 20, 23, 26
and 30 nM). After 14 days (d), foci were scored and
each sample was normalized by transfection efficiency
set to 100% as the starting value under conditions of no
Gantespib. Mock transfected cells and cells expressing
FGFR1 were also included in this assay; no foci were
observed. (B) Effects of Ganetespib (15 nM) together
with increasing concentrations of FGFR-specific TKI
BGJ398 in NIH3T3 transformation assays. Quantitation
as in (A) above. Mock transfected cells and cells
expressing FGFR1 were also included in this assay;
again, no foci were observed (C and D). Ganetespib
inhibits 32D cell proliferation stimulated by BCR-FGFR1.
32D control cells and cells selectively expressing BCR-
FGFR1 were cultured in panel C in the absence of IL-3
and, in panel D, in the presence of IL-3, together with
Ganetespib at 0, 2.5, and 5.0 nM. Cells expressing
FGFR1 were also included in this assay and showed no
cell proliferation in the absence of IL-3, as shown earlier
(Figure 3A and D). Cell viability was determined by MTT
metabolic assay. All control cells and cell lines were
assayed in triplicate. Standard error is shown.
A
B
C
D
Ganetespib (Figure 7A).  The BCR-FGFR1 derivatives were
more sensitive to the Ganetespib than FGFR1-K656E, pos-
sibly due to the lack of HSP90 association with FGFR1-
K656E (Figure 6).
Furthermore, in order to determine if the effects of
Ganetespib were synergistic with FGFR inhibition, a com-
binatorial experiment was performed on NIH3T3 cells
expressing either BCR-FGFR1 or FGFR1 derivatives,
which were simultaneously treated with Ganetespib and
a TKI. These cells were treated with a constant 15 nM
Ganetespib and were dosed with increasing concentra-
tions of BGJ398, a potent FGFR inhibitor (Figure 7B). A
potentially synergistic effect is observed between
Ganetespib and BGJ398, as foci production among cells
expressing either BCR-FGFR1 or FGFR1 derivatives dra-
matically decreases. These data suggest that the use of
Hsp90 inhibition combined with TKI treatment may be
beneficial for BCR-FGFR1 expressing cells. 
The effect of Ganetespib was also examined using 32D
IL-3-dependent cells. The IL-3-independent proliferation
of the BCR-FGFR1 expressing 32D cells was reduced by
treatment with Ganetespib as measured by MTT assay
(Figure 7C). The Ganetespib did not affect the normal
dependence of the cells on IL-3, as shown in Figure 7D.
Therefore, these data suggest that BCR-FGFR1 is depend-
ent on the molecular chaperone Hsp90 for cellular trans-
formation.
Discussion 
Considerable advances have been made in our under-
standing of the molecular basis of hematological cancers.
Since the identification of BCR-ABL almost 60 years ago,29
over 500 oncogenic translocations have been identified in
hematopoietic cancers alone, which emphasizes the
importance of identifying and characterizing these onco-
genic drivers.30 With the emergence of personalized medi-
cine, the characterization of activators of SCLL, such as
BCR-FGFR1, is critical in determining additional therapeu-
tic targets. Although the use of TKI to treat SCLL is
becoming more commonplace, TKI treatment often
results in drug resistance in patients, highlighting the need
for additional therapies for SCLL.31
Biological and biochemical characterization of 
BCR-FGFR1 
Through the data presented, we were able to extensive-
ly characterize the fusion protein BCR-FGFR1. We
demonstrate that the N-terminal fusion of BCR results in
constitutive activation of FGFR1. Through our cell signal-
ing studies, we demonstrate that BCR-FGFR1 activates
ERK/MAPK and JAK/STAT pathways, and possesses
transforming activity in NIH3T3 cells (Figure 1-2).
However, BCR-FGFR1-K514A was unable to activate
either pathway, or transform NIH3T3 cells, indicating that
BCR-FGFR1 relies on the kinase activity of FGFR1 for acti-
vation. Furthermore, 32D cells expressing BCR-FGFR1 or
BCR-FGFR1-K656E were able to proliferate in the absence
of IL-3, indicating the oncogenic potential of this fusion
protein (Figure 3).
LC-MS/MS data additionally demonstrate that BCR-
FGFR1 relies on the kinase activity of FGFR1 for onco-
genic activity. Phosphorylation on key tyrosine residues in
the FGFR1 kinase domain, including Y653 and Y654 in the
activation loop, is observed in BCR-FGFR1 and BCR-
FGFR1-K656E, which is absent in kinase-dead BCR-
FGFR1-K514A (Figure 4). Although novel phosphorylation
sites were detected on BCR, these phosphoacceptor sites
do not appear to be critical for the cell transformation or
oncogenic ability of BCR-FGFR1 (Table 1). 
Novel therapeutic targets for SCLL induced by 
BCR-FGFR1 
Currently, hematopoietic stem cell transplantation is the
primary curative option for patients who have SCLL.
Here, we have described two novel potential therapeutic
approaches: disruption of ionic bonding that stabilizes
BCR oligomerization, and inhibition of the chaperonin
Hsp90 complex. 
The coiled-coil oligomerization domain of BCR has pre-
viously been demonstrated to be essential for the trans-
forming ability of BCR-ABL.21 However, the requirement
of electrostatic interactions within the coiled-coil domain
for oligomerization has not been investigated. Here, we
have described a novel inhibition of BCR-FGFR1 mediated
cell transformation through abolishing three salt bridge
interactions in the coiled-coil domain of BCR. This abla-
tion of cell transformation is seen through focus forming
assays, as the disruption of these salt bridges in the 
BCR-FGFR1 mutant E34R/E46R/E52R (mutant 11) almost
completely abolishes focus formation (Figure 5).
Furthermore, the intrahelical Salt Bridge #3, formed by
residue Glu52 with Arg55 in BCR, plays a crucial role in
providing stability for the coiled-coil domain in BCR. The
apparent ability of Arg55 to form complex salt bridges
with Glu34 and Glu52 highlights the potential importance
of cooperativity exhibited by complex salt bridges and
their contribution to protein stability.32 Taken together,
these data suggest that these three salt bridges provide a
critical role in the activation of BCR-FGFR1. The potential
loss of oligomerization and near absence in focus forma-
tion suggests that the coiled-coil domain of BCR is an
attractive therapeutic target for SCLL. 
Additionally, we have shown that BCR-FGFR1 is a
client of the Hsp90 chaperone complex, and potentially
uses this complex to avoid proteasomal degradation in the
cell. Previous work has shown that the FGFR1OP2-FGFR1
fusion is also a client of the Hsp90 complex, and that tar-
geting the Hsp90 complex resulted in reduced activity of
this fusion protein.33 The interaction and dependence of
BCR-FGFR1 on the Hsp90 complex is established through
cell transformation assays, and analysis of downstream
cell signaling (Figure 6-7). A decrease in overall expression
of BCR-FGFR1 is detected with the addition of
Ganetespib, a potent Hsp90 inhibitor. Furthermore, BCR-
FGFR1 expressing cells treated with Ganetespib displayed
a reduction in STAT and MAPK activation, and no FGFR1
phosphorylation. Additionally, the transformation ability
of cells expressing BCR-FGFR1 decreases when treated
with increasing concentrations of Ganetespib (Figure 7A),
indicating that this fusion protein relies on the Hsp90
complex for cellular stability, and is sensitive to Hsp90
inhibition. We also examined the combined effects of
Ganetespib with the FGFR inhibitor BGJ398 in NIH3T3
cell transformation assays (Figure 7B), and in 32D cell pro-
liferation assays in the absence and presence of IL-3
(Figure 7C-D). Taken together, these data show that BCR-
FGFR1 may rely on the Hsp90 molecular chaperone com-
plex to avoid proteasomal degradation.34
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Through this work, we have described potential
approaches to inhibit BCR-FGFR1 induced SCLL.
Although TKI therapies have been used to traditionally
treat certain hematopoietic cancers, their use has often
resulted in drug resistance. Recently it has been discovered
that FGFR1 fusion kinases are associated with the upregu-
lation of MYC, which drives SCLL.35 Targeting the MYC
complex in addition to chemotherapy, and the approaches
described here may also be therapeutically beneficial for
patients with SCLL. 
Relevance for BCR-ABL driven cancers 
Since the initial characterization of BCR-ABL, the emer-
gence of cancer genome sequencing has played a vital role
in the detection of other translocation-induced malig-
nances. BCR-ABL is detected in 95% of CML cases, and
variants of this gene exist with alternative breakpoints.
The most commonly found transcript is the BCR-ABL
p210 variant which contains a breakpoint of BCR exon 13
fused to exon 1 of ABL.10 In comparison to BCR-FGFR1,
BCR-ABL retains more of the BCR gene in this fusion.
However, both fusions retain the oligomerization domain,
putative serine threonine/kinase domain and GEF domain.
Due to the similarity between these fusions, we propose
that the work described here will be relevant to BCR-ABL
fusions as well. In particular, the inhibition of the BCR
coiled-coil domain through salt bridge disruption may be
an additional therapeutic target for BCR-ABL.
Furthermore, retention of the GEF domain in BCR-FGFR1
has been shown to result in reduced leukemogenesis.36
Although TKI are usually the first line of treatment for
CML, many patients will require concurrent forms of ther-
apy to ensure complete remission.37 Hsp90 inhibition has
become an attractive therapeutic target in treating 
BCR-ABL induced CML. More recently, aminoxyrone was
shown to be effective in inhibiting imatinib resistant
CML.37 While Ganetespib binds to the N-terminal ATP
binding site in Hsp90, Aminoxyrone binds to the C-termi-
nal tail of Hsp90, preventing its dimerization. The combi-
nation of Hsp90 inhibition with traditional chemotherapy
and TKI treatment may be beneficial in patients with
CML or SCLL. These recent findings again highlight the
importance of the characterization of oncogenic transloca-
tions as well as the development of additional therapeutic
targets to treat therapy-refractory leukemia. 
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